← Browse by Condition
Medical Condition

systemic therapy

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for systemic therapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — systemic therapy Clinical Trials

How many clinical trials are currently recruiting for systemic therapy?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for systemic therapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for systemic therapy?
systemic therapy research spans Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a systemic therapy clinical trial?
Eligibility criteria for systemic therapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
1
Top Sponsors
Sun Yat-sen University 2 trials
Shandong Cancer Hospital and Institute 1 trial

Recruiting Clinical Trials

NCT06788353
Recruiting
Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
Enrollment
500 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06841172 Phase 3
Recruiting
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
Enrollment
132 pts
Location
China
Sponsor
Shandong Cancer Hospital and I...
View Trial →
NCT06644430
Recruiting
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Enrollment
470 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →

Related Conditions

transarterial chemoembolization (1) unresectable hepatocellular carcinoma (1) oligoprogressive metastatic disease (1) hepatocellular carcinoma hcc (1) radiotherapy (1) advanced hepatocellular carcinoma (1) lung cancer (1) oligometastasis (1) ablation (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology